Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Recruiting · NCT06441747 · Registry updated 2026-05-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 2 | 2026-05-06 | NCT06441747 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Australasian Gastro-Intestinal Trials Group | 10 |
| Wayne Elphinstone Research Fund | 1 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Austin Health | Melbourne | Australia | 16 |
| Chris O'Brien Lifehouse | Camperdown | Australia | 46 |
| Flinders Medical Centre | Bedford Park | Australia | 6 |
| Monash Medical Centre | Clayton | Australia | 1 |
| Princess Alexandra Hospital | Woolloongabba | Australia | 106 |
| Royal North Shore Hospital | St Leonards | Australia | 50 |
| Westmead Hospital | Westmead | Australia | 128 |
| Wollongong and Shoalhaven District Memorial Hospital | Wollongong | Australia | 1 |